Current and future immunotherapies for thyroid cancer.

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Cancer immunotherapies, including immune checkpoint inhibitors (ICIs) targeting CTLA-4, PD-1, and PD-L1, have demonstrated significant impact on overall survival in various cancers.
• Thyroid cancer (TC) cells can promote tumor growth by producing cytokines and chemokines, and increased regulatory T cells (Tregs) and PD-1+ T cells are associated with aggressive disease.
• PD-L1 expression in TC correlates with an increased risk of recurrence, suggesting a potential role for immunotherapy.

Purpose of the Study:

• To review the current landscape of immunotherapy in thyroid cancer.
• To highlight the potential therapeutic benefits of targeting immune checkpoints in aggressive TC.
• To underscore the need for further clinical investigation of ICIs in TC.

Main Methods:

• Literature search to identify studies evaluating immunotherapy in thyroid cancer.
• Review of existing data on the efficacy and safety of ICIs in various cancer types.
• Analysis of the role of cytokines, chemokines, Tregs, and PD-L1 expression in TC pathogenesis.

Main Results:

• Pioneering studies have begun to explore immunotherapy in TC, with some showing promising results.
• A recent case report demonstrated substantial regression and complete remission in anaplastic thyroid cancer treated with vemurafenib and nivolumab.
• Response rates for ICIs in other cancers typically range from 20% to 40%.

Conclusions:

• Immune checkpoint inhibitors represent a promising therapeutic avenue for aggressive thyroid cancer.
• Targeting the tumor microenvironment by modulating cytokines and chemokines may offer therapeutic benefits.
• Extensive clinical trials involving a larger cohort of TC patients are urgently required to establish the efficacy and safety of ICIs in this disease.